Journals should select drug advertisements more carefullyBMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7400.1211 (Published 29 May 2003) Cite this as: BMJ 2003;326:1211
- James J Oliver, specialist registrar in clinical pharmacology ([email protected]),
- Simon R Maxwell, senior lecturer in clinical pharmacology
- Clinical Pharmacology Unit, Western General Hospital, Edinburgh EH4 2XU
EDITOR—Until the ALLHAT study (antihypertensive and lipid lowering treatment to prevent heart attack trial) was published,1 there was little, if any, evidence of the clinical benefit of amlodipine in treating hypertension. Nevertheless, as testimony to the marketing success of Pfizer, amlodipine has become the world's biggest selling antihypertensive drug.
Pfizer is obviously keen to publicise the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial